Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis

Breast Cancer Research - 2012
Arumugam Nagalingam1, Jack L Arbiser2, Michael Y Bonner2, Neeraj K Saxena3, Dipali Sharma1
1Department of Oncology, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
2Department of Dermatology, Emory University School of Medicine, Winship Cancer Institute, Atlanta
3Department of Medicine, University of Maryland School of Medicine, Baltimore

Tóm tắt

Honokiol, a small-molecule polyphenol isolated from magnolia species, is widely known for its therapeutic potential as an antiinflammatory, antithrombosis, and antioxidant agent, and more recently, for its protective function in the pathogenesis of carcinogenesis. In the present study, we sought to examine the effectiveness of honokiol in inhibiting migration and invasion of breast cancer cells and to elucidate the underlying molecular mechanisms. Clonogenicity and three-dimensional colony-formation assays were used to examine breast cancer cell growth with honokiol treatment. The effect of honokiol on invasion and migration of breast cancer cells was evaluated by using Matrigel invasion, scratch-migration, spheroid-migration, and electric cell-substrate impedance sensing (ECIS)-based migration assays. Western blot and immunofluorescence analysis were used to examine activation of the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) axis. Isogenic LKB1-knockdown breast cancer cell line pairs were developed. Functional importance of AMPK activation and LKB1 overexpression in the biologic effects of honokiol was examined by using AMPK-null and AMPK-wild type (WT) immortalized mouse embryonic fibroblasts (MEFs) and isogenic LKB1-knockdown cell line pairs. Finally, mouse xenografts, immunohistochemical and Western blot analysis of tumors were used. Analysis of the underlying molecular mechanisms revealed that honokiol treatment increases AMP-activated protein kinase (AMPK) phosphorylation and activity, as evidenced by increased phosphorylation of the downstream target of AMPK, acetyl-coenzyme A carboxylase (ACC) and inhibition of phosphorylation of p70S6kinase (pS6K) and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1). By using AMPK-null and AMPK-WT (MEFs), we found that AMPK is required for honokiol-mediated modulation of pACC-pS6K. Intriguingly, we discovered that honokiol treatment increased the expression and cytoplasmic translocation of tumor-suppressor LKB1 in breast cancer cells. LKB1 knockdown inhibited honokiol-mediated activation of AMPK and, more important, inhibition of migration and invasion of breast cancer cells. Furthermore, honokiol treatment resulted in inhibition of breast tumorigenesis in vivo. Analysis of tumors showed significant increases in the levels of cytoplasmic LKB1 and phospho-AMPK in honokiol-treated tumors. Taken together, these data provide the first in vitro and in vivo evidence of the integral role of the LKB1-AMPK axis in honokiol-mediated inhibition of the invasion and migration of breast cancer cells. In conclusion, honokiol treatment could potentially be a rational therapeutic strategy for breast carcinoma.

Từ khóa


Tài liệu tham khảo

Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003, 3: 768-780. 10.1038/nrc1189.

Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003, 66: 1022-1037. 10.1021/np030096l.

Fried LE, Arbiser JL: Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009, 11: 1139-1148. 10.1089/ars.2009.2440.

Fujita M, Itokawa H, Sashida Y: [Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants]. Yakugaku Zasshi. 1973, 93: 429-434.

Konoshima T, Kozuka M, Tokuda H, Nishino H, Iwashima A, Haruna M, Ito K, Tanabe M: Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J Nat Prod. 1991, 54: 816-822. 10.1021/np50075a010.

Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G: Arbiser: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003, 278: 35501-35507. 10.1074/jbc.M302967200.

Battle TE, Arbiser J, Frank DA: The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 2005, 106: 690-697. 10.1182/blood-2004-11-4273.

Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW: Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007, 109: 1279-1289. 10.1002/cncr.22551.

Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, Brown HA, Bar-Sagi D, Foster DA, Arbiser JL: Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 2008, 14: 4267-4274. 10.1158/1078-0432.CCR-08-0102.

Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, Yan S, Jiang G, Zhou L, Zheng S: Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 2008, 28: 1458-1464. 10.1111/j.1478-3231.2008.01767.x.

Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, Chen L, Wei Y: Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008, 140: 95-102. 10.1016/j.ejogrb.2008.02.023.

Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC: Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005, 106: 1794-1800. 10.1182/blood-2005-01-0346.

Zhu W, Fu A, Hu J, Wang T, Luo Y, Peng M, Ma Y, Wei Y, Chen L: 5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway. Exp Mol Med. 2011, 43: 146-152. 10.3858/emm.2011.43.3.017.

Lee YK, Choi IS, Kim YH, Kim KH, Nam SY, Yun YW, Lee MS, Oh KW, Hong JT: Neurite outgrowth effect of 4-O-methylhonokiol by induction of neurotrophic factors through ERK activation. Neurochem Res. 2009, 34: 2251-2260. 10.1007/s11064-009-0024-7.

Zhai H, Nakade K, Oda M, Mitsumoto Y, Akagi M, Sakurai J, Fukuyama Y: Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur J Pharmacol. 2005, 516: 112-117. 10.1016/j.ejphar.2005.04.035.

Sheu ML, Chiang CK, Tsai KS, Ho FM, Weng TI, Wu HY, Liu SH: Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med. 2008, 44: 2043-2050. 10.1016/j.freeradbiomed.2008.03.014.

Tse AK, Wan CK, Shen XL, Yang M, Fong WF: Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem Pharmacol. 2005, 70: 1443-1457. 10.1016/j.bcp.2005.08.011.

Lee J, Jung E, Park J, Jung K, Lee S, Hong S, Park E, Kim J, Park S, Park D: Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med. 2005, 71: 338-343. 10.1055/s-2005-864100.

Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB: Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 2006, 4: 621-633. 10.1158/1541-7786.MCR-06-0076.

Kim SH, Nagalingam A, Saxena NK, Singh SV, Sharma D: Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis. 2011, 32: 359-367. 10.1093/carcin/bgq267.

Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B: 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol. 2006, 26: 5336-5347. 10.1128/MCB.00166-06.

Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D: LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009, 28: 2621-2633. 10.1038/onc.2009.129.

Saxena NK, Vertino PM, Anania FA, Sharma D: Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem. 2007, 282: 13316-13325. 10.1074/jbc.M609798200.

Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D: Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer. 2011, 18: 413-428. 10.1530/ERC-11-0075.

Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK: Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010, 52: 1713-1722. 10.1002/hep.23892.

Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, Tighiouart M, Sharma D, Anania FA: Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010, 139: 1762-1773. 10.1053/j.gastro.2010.07.001. 1773, e1761-1765

Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, Sharma D: Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008, 68: 9712-9722. 10.1158/0008-5472.CAN-08-1952.

Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67: 2497-2507. 10.1158/0008-5472.CAN-06-3075.

Steeg PS, Theodorescu D: Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol. 2008, 5: 206-219. 10.1038/ncponc1066.

Lauffenburger DA, Horwitz AF: Cell migration: a physically integrated molecular process. Cell. 1996, 84: 359-369. 10.1016/S0092-8674(00)81280-5.

Friedl P, Brocker EB: The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci. 2000, 57: 41-64. 10.1007/s000180050498.

Schlaepfer DD, Mitra SK, Ilic D: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta. 2004, 1692: 77-102. 10.1016/j.bbamcr.2004.04.008.

Siesser PM, Hanks SK: The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res. 2006, 12: 3233-3237. 10.1158/1078-0432.CCR-06-0456.

Hardie DG: Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr. 2011, 93: 891S-896S. 10.3945/ajcn.110.001925.

Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J: LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle. 2011, 10: 2115-2120. 10.4161/cc.10.13.16244.

Hadad SM, Fleming S, Thompson AM: Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008, 67: 1-7. 10.1016/j.critrevonc.2008.01.007.

Hardie DG: The AMP-activated protein kinase pathway: new players upstream and downstream. J Cell Sci. 2004, 117: 5479-5487. 10.1242/jcs.01540.

Motoshima H, Goldstein BJ, Igata M, Araki E: AMPK and cell proliferation: AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006, 574: 63-71. 10.1113/jphysiol.2006.108324.

Luo Z, Saha AK, Xiang X, Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005, 26: 69-76. 10.1016/j.tips.2004.12.011.

Martin DE, Hall MN: The expanding TOR signaling network. Curr Opin Cell Biol. 2005, 17: 158-166. 10.1016/j.ceb.2005.02.008.

Ip CK, Cheung AN, Ngan HY, Wong AS: p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011, 30: 2420-2432. 10.1038/onc.2010.615.

Pantaloni D, Le Clainche C, Carlier MF: Mechanism of actin-based motility. Science. 2001, 292: 1502-1506. 10.1126/science.1059975.

Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 2007, 12: 9-22. 10.1016/j.ccr.2007.05.008.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005, 307: 1098-1101. 10.1126/science.1106148.

Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK: Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett. 2009, 277: 133-140. 10.1016/j.canlet.2008.11.029.

Vaahtomeri K, Makela TP: Molecular mechanisms of tumor suppression by LKB1. FEBS Lett. 2011, 585: 944-951. 10.1016/j.febslet.2010.12.034.

Hardie DG: New roles for the LKB1→AMPK pathway. Curr Opin Cell Biol. 2005, 17: 167-173. 10.1016/j.ceb.2005.01.006.

Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM: The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res. 2002, 8: 2085-2090.

Phoenix KN, Vumbaca F, Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009, 113: 101-111. 10.1007/s10549-008-9916-5.

Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP: Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet. 2002, 11: 1497-1504. 10.1093/hmg/11.13.1497.

Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways. Annu Rev Biochem. 2006, 75: 137-163. 10.1146/annurev.biochem.75.103004.142702.

Smith DP, Spicer J, Smith A, Swift S, Ashworth A: The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase. Hum Mol Genet. 1999, 8: 1479-1485. 10.1093/hmg/8.8.1479.

Su JY, Erikson E, Maller JL: Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos. J Biol Chem. 1996, 271: 14430-14437. 10.1074/jbc.271.24.14430.

Watts JL, Morton DG, Bestman J, Kemphues KJ: The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry. Development. 2000, 127: 1467-1475.

Tiainen M, Ylikorkala A, Makela TP: Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA. 1999, 96: 9248-9251. 10.1073/pnas.96.16.9248.

Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, Brien TP, Bozzuto CD, Ooi D, Cantley LC, Yuan J: The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell. 2001, 7: 1307-1319. 10.1016/S1097-2765(01)00258-1.

Ghaffar H, Sahin F, Sanchez-Cepedes M, Su GH, Zahurak M, Sidransky D, Westra WH: LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res. 2003, 9: 2998-3003.

Sahin F, Maitra A, Argani P, Sato N, Maehara N, Montgomery E, Goggins M, Hruban RH, Su GH: Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol. 2003, 16: 686-691. 10.1097/01.MP.0000075645.97329.86.

Wei C, Amos CI, Rashid A, Sabripour M, Nations L, McGarrity TJ, Frazier ML: Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. J Histochem Cytochem. 2003, 51: 1665-1672. 10.1177/002215540305101210.

Kline ER, Muller S, Pan L, Tighiouart M, Chen ZG, Marcus AI: Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis. Head Neck. 2010, 33: 1501-1512.

Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, Sahin F, Su GH, Argani P: LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol. 2006, 14: 146-153. 10.1097/01.pai.0000176157.07908.20.

Fang X, Palanivel R, Cresser J, Schram K, Ganguly R, Thong FS, Tuinei J, Xu A, Abel ED, Sweeney G: An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol Metab. 2010, 299: E721-E729. 10.1152/ajpendo.00086.2010.

Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, Zhang N, Musi N, DeFronzo RA, Liu F, Dong LQ: APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol Endocrinol. 2011, 25: 1773-1785. 10.1210/me.2011-0082.

Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, Liu DD, Torres JM, Jia W, Lechleiter JD, Liu F, Dong LQ: Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem. 2009, 284: 22426-22435. 10.1074/jbc.M109.028357.

Zeng PY, Berger SL: LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 2006, 66: 10701-10708. 10.1158/0008-5472.CAN-06-0999.

Nath-Sain S, Marignani PA: LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol Biol Cell. 2009, 20: 2785-2795. 10.1091/mbc.E08-11-1138.

Sebbagh M, Santoni MJ, Hall B, Borg JP, Schwartz MA: Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol. 2009, 19: 37-42. 10.1016/j.cub.2008.11.033.

Goel A, Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010, 62: 919-930. 10.1080/01635581.2010.509835.

Stuart EC, Scandlyn MJ, Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci. 2006, 79: 2329-2336. 10.1016/j.lfs.2006.07.036.

Juge N, Mithen RF, Traka M: Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007, 64: 1105-1127. 10.1007/s00018-007-6484-5.

Nakamura Y: Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. Forum Nutr. 2009, 61: 170-181.

Bar-Sela G, Epelbaum R, Schaffer M: Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010, 17: 190-197. 10.2174/092986710790149738.

Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, Deng C, Wen J, Wang N, Peng C, Zhao X, Wei Y, Chen L: Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One. 2011, 6: e18490-10.1371/journal.pone.0018490.

Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998, 18: 38-43. 10.1038/ng0198-38.

Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, Alessi DR: MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 2003, 22: 5102-5114. 10.1093/emboj/cdg490.

Smith DP, Rayter SI, Niederlander C, Spicer J, Jones CM, Ashworth A: LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. Hum Mol Genet. 2001, 10: 2869-2877. 10.1093/hmg/10.25.2869.

Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR, Clevers HC: Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003, 22: 3062-3072. 10.1093/emboj/cdg292.

Xie Z, Dong Y, Scholz R, Neumann D, Zou MH: Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008, 117: 952-962. 10.1161/CIRCULATIONAHA.107.744490.

Xie Z, Dong Y, Zhang M, Cui MZ, Cohen RA, Riek U, Neumann D, Schlattner U, Zou MH: Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem. 2006, 281: 6366-6375. 10.1074/jbc.M511178200.

Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou MH: Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem. 2008, 283: 12446-12455. 10.1074/jbc.M708208200.

Thông tin
Thông tin xuất bản

Breast Cancer Research

Thông tin tác giả